Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA-B receptor agonist1,4-Butanediol
1,4-Butanediol (butane-1,4-diol) is a synthetic depressant of the aliphatic diol class. It is a prodrug of GHB, meaning it is chemically inert until the body converts it. This conversion produces GHB, which activates GABA receptors in the brain[1][2] and produces the sedation and euphoria characteristic of CNS depressants.
1,4-Butanediol (butane-1,4-diol) is a synthetic depressant of the aliphatic diol class. It is a prodrug of GHB, distinguished by its delayed onset and extended duration. 1,4-Butanediol is pharmacologically inert until metabolized to GHB, which activates GABA-B receptors as a weak partial agonist.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA-B receptor agonistIts pharmacological significance was established in 1984, when researchers first demonstrated its conversion to GHB inside the body.[3] When the United States scheduled GHB in 2000, 1,4-BD emerged as a legal substitute — an unscheduled industrial chemical available from bulk chemical suppliers.[4][5] It now circulates primarily in chemsex and nightlife settings across Europe and Australasia.[6]
Subjective effects include euphoria, warmth, disinhibition, enhanced sociability, and sedation. The experience resembles a cleaner, more euphoric version of alcohol intoxication — warm and loosening at first, then shifting abruptly into heavy sedation as the dose rises. Amnesia, nausea, and sudden loss of consciousness are characteristic unsought effects.
1,4-BD produces rapid physical dependence, and the margin between a euphoric and a fatal dose is one of the narrowest among recreational depressants.[7] A genetic variation in the converting enzyme can make the same dose up to four times more potent in some people than others,[8] making individual responses unpredictable. One controlled human study exists;[8] current understanding rests heavily on GHB data and case reports.
History[edit]
Discovery
1,4-Butanediol has been manufactured industrially for decades as a feedstock for plastics and solvents.[5] In 1984, researchers demonstrated that it converts to GHB inside the body and interacts with ethanol at the metabolic level.[3] GHB itself was first synthesized in 1960 as a GABA-like compound designed to enter the brain.[4]
Recreational adoption and scheduling
GHB gained popularity in bodybuilding and club scenes during the 1980s and 90s,[4] and reports of its use in sexual assault attracted legislative attention.[6][9] The United States scheduled GHB in 2000,[4] and 1,4-BD emerged as an unscheduled industrial substitute.[5][10]
Modern use
1,4-BD now features prominently in chemsex contexts, particularly among men who have sex with men, often combined with methamphetamine and mephedrone.[6] Treatment admissions for GHB-related dependence have risen sharply in the Netherlands and other European countries.[11] Deaths have been documented across Australasia[12] and the Nordic countries.[13]
The name 1,4-butanediol describes its structure: a four-carbon chain with alcohol groups at positions 1 and 4. Common abbreviations are 1,4-BD and BDO. Its status as an unrestricted industrial solvent that converts in the body to one of the most tightly controlled recreational depressants makes it a recurring example of the limits of structural analog-based drug scheduling.
Chemistry[edit]
Structural class
1,4-Butanediol belongs to the alkanediol chemical family — a four-carbon chain with alcohol groups at each end. It is structurally distinct from both GHB and GBL, but all three convert to GHB once inside the body.[14] Its molecular formula is C₄H₁₀O₂, with a molecular weight of 90.12 g/mol.
The conversion proceeds through two enzyme steps: alcohol dehydrogenase first, then aldehyde dehydrogenase. The molecule has no ring structure, no nitrogen atoms, and no aromatic features. It is achiral — a single molecular species with no mirror-image forms.
Pharmacology[edit]
Mechanism of action
1,4-Butanediol is pharmacologically inert — a prodrug that must be converted to GHB by the body before producing any effects. Two enzymes perform this conversion: alcohol dehydrogenase (ADH) first, then aldehyde dehydrogenase (ALDH).[15] The ADH step is the bottleneck — blocking it with the drug fomepizole prevents intoxication entirely.[16]
Once formed, GHB activates GABA receptors — the brain's primary inhibitory system.[1][2] When GABA-B receptors are knocked out in animals, all GHB effects disappear.[17] GHB also appears to act on a separate GHB-specific receptor that drives its euphoric and prosocial effects — effects that don't occur with pure GABA drugs like baclofen.[18][19]
Pharmacokinetics
In the one controlled human study, 1,4-BD peaked in the blood at about 24 minutes and cleared with a half-life of around 39 minutes.[8] The GHB metabolite peaked later, which explains why 1,4-BD produces a longer experience than GHB taken directly.[20][10] A genetic variant in ADH — the ADH1B G143A variant — slows conversion four-fold, making the same dose dramatically more intense for those who carry it.[8]
Neuroscience[edit]
Where it acts
All of 1,4-butanediol's effects in the brain come from its GHB metabolite. GHB activates GABA receptors, slowing neural activity and producing sedation, muscle relaxation, and anxiety relief.[21] In the brain's reward circuit, it also releases dopamine by lifting inhibition on dopamine neurons — at low doses producing euphoria, at higher doses overtaken by sedation.[18][11]
Why it matters
GHB activates mood-regulating brain regions that pure GABA drugs do not reach.[22] This explains the prosocial, euphoric, and sexually arousing effects that set GHB-type compounds apart from other sedatives.
With chronic use, the brain adapts across multiple systems.[11] When the drug is removed, an overactive glutamate response drives the seizures, delirium, and instability that define withdrawal.
Whether the GHB-specific binding site independently drives euphoria — separate from GABA activation — remains unknown.[17] Chronic users show deficits in memory and attention,[23] but no human brain imaging study has assessed structural damage. No dose-response data across the euphoric-to-sedating range exist under controlled conditions.[8]
Subjective Effects[edit]
The 1,4-butanediol experience is defined by its prodrug pharmacology: the slow enzymatic conversion to GHB creates a gradual build into warmth, sociability, and euphoria. The experience tips sharply into heavy sedation and amnesia — the transition is faster and less forgiving than most depressants, and the dose window between pleasurable and incapacitating is unusually narrow.
Compared to alcohol, 1,4-BD produces more pronounced euphoria and greater sexual disinhibition, with a steeper slide into incapacitation. Compared to GHB taken directly, the onset is slower and the total duration longer — a gentler arc, but one that extends the window of risk.
Identified as a GHB precursor in 1984 through work demonstrating its in vivo conversion,[3] 1,4-butanediol entered recreational use after GHB was scheduled in the United States in 2000.[4] Its dual identity as a bulk industrial chemical and unscheduled precursor created a persistent regulatory gap.[5] It now circulates primarily in chemsex and nightlife contexts across Europe and Australasia.[6]
Subjective effects include euphoria, anxiolysis, disinhibition, enhanced sociability, and sedation. The experience resembles a cleaner, more euphoric alcohol intoxication — warm sociability and loosened inhibition that shifts abruptly toward heavy sedation as dose increases. Amnesia, nausea, and sudden loss of consciousness are characteristic unsought effects.
1,4-Butanediol produces rapid physical dependence with continuous use, and its GHB metabolite has one of the narrowest margins between a euphoric and fatal dose among recreational depressants.[7] Genetic variation in alcohol dehydrogenase creates up to four-fold differences in conversion rate,[8] making identical doses unpredictably potent between individuals. A single controlled human pharmacokinetic study has been published;[8] the current understanding rests heavily on GHB data and case reports.
History[edit]
Discovery
1,4-Butanediol has been manufactured for decades as an industrial feedstock for tetrahydrofuran, spandex, and polyurethane production.[5] Its pharmacological significance emerged in 1984 when Poldrugo and Snead demonstrated that 1,4-BD converts to GHB in vivo and interacts with ethanol at the metabolic level.[3] GHB itself — the compound 1,4-BD ultimately becomes — had been synthesized by Henri Laborit in 1960 as a GABA structural analog designed to cross the blood-brain barrier.[4]
Recreational adoption and scheduling
During the 1980s, GHB gained popularity in bodybuilding communities for purported growth hormone–stimulating effects, and its precursors including 1,4-BD were sold without restriction through supplement channels.[4] By the late 1990s, GHB had become an established club drug valued for its euphoric and disinhibiting properties, while concurrent reports of its use in drug-facilitated sexual assault attracted legislative attention.[6][9] The United States designated GHB as Schedule I in 2000 under the Hillory J. Farias and Samantha Reid Date-Rape Drug prohibition Act, while simultaneously placing FDA-approved sodium oxybate (Xyrem) on Schedule III.[4]
Modern use
GHB scheduling triggered a predictable substitution pattern: 1,4-BD and GBL emerged as preferred alternatives because they remained unscheduled industrial chemicals with ready commercial availability.[5][10] Both compounds now feature prominently in chemsex contexts, particularly among men who have sex with men, frequently combined with methamphetamine and mephedrone.[6] Treatment admissions for GHB-related dependence have risen sharply in the Netherlands and other European countries,[11] and fatalities have been documented across Australasia[12] and the Nordic countries.[13]
The name 1,4-butanediol derives from its chemical structure: a four-carbon (butane) chain with hydroxyl groups (diol) at the 1 and 4 positions. Common abbreviations include 1,4-BD and BDO. Its reputation in drug culture is shaped by paradox — an unrestricted industrial solvent purchasable in bulk from chemical suppliers, yet one that converts in the body to one of the most tightly controlled recreational depressants. This regulatory gap has made it a recurring example of the limits of analogue-based drug scheduling.
Chemistry[edit]
Structural class
1,4-Butanediol belongs to the alkanediol (diol) chemical class — a four-carbon aliphatic chain bearing hydroxyl groups at the 1 and 4 positions. It is structurally distinct from its active metabolite GHB (a gamma-hydroxy carboxylic acid) and from GBL (a cyclic lactone), though all three converge on GHB as the common active species in vivo.[14]
The conversion pathway is linear: 1,4-BD undergoes oxidation to 4-hydroxybutyraldehyde (via ADH), then to GHB (via ALDH), while GBL converts to GHB through lactonase-mediated ring-opening.
Molecular properties
| Molecular formula | C₄H₁₀O₂ |
| Molecular weight | 90.12 g/mol |
The molecule consists of a linear four-carbon backbone with terminal hydroxyl groups. It contains no ring systems, no nitrogen atoms, and no aromatic features. At 90.12 g/mol, it is one of the smallest psychoactive prodrugs in recreational use.
Stereochemistry
1,4-Butanediol is achiral. Both hydroxyl groups sit on a symmetric carbon chain, producing a single molecular species with no enantiomers or diastereomers.
Physical properties
1,4-Butanediol presents as a colorless, viscous, water-miscible liquid at room temperature with a faint, slightly sweet odor and minimal taste at low concentrations — properties that have contributed to its documented use in drug-facilitated sexual assault.
| Melting point | 16 °C |
| Boiling point | 230 °C |
| Solubility | Freely miscible with water |
The compound is stable under normal storage conditions and does not convert to GHB outside biological systems. Its water miscibility and near-unit density (approximately 1.0 g/mL) mean that volumetric dosing in milliliters approximates mass dosing in grams.
Pharmacology[edit]
Mechanism of action
1,4-Butanediol is pharmacologically inert — a prodrug requiring metabolic conversion to gamma-hydroxybutyric acid (GHB) before producing any psychoactive effects. This conversion proceeds through two enzymatic steps: alcohol dehydrogenase (ADH) oxidizes 1,4-BD to 4-hydroxybutyraldehyde, and aldehyde dehydrogenase (ALDH) converts that intermediate to GHB.[15] The ADH step is rate-limiting, confirmed in human liver preparations[15] and in living humans via the ADH inhibitor fomepizole.[16]
Once formed, GHB acts primarily through the GABA-B receptor as a weak partial agonist.[1][2] Genetic and pharmacological evidence identifies GABA-B as the essential mediator: GABA-B1 knockout mice lose all GHB effects,[17] and GABA-B antagonists fully block sedation and related behavioral effects.[18][19][20]
A distinct high-affinity GHB-specific receptor may mediate the prosocial and euphoric effects that set GHB apart from pure GABA-B agonists like baclofen.[21][22] GHB also modulates dopamine release in the brain’s reward circuitry, contributing to its euphoriant and reinforcing properties.[21][11] Chronic exposure additionally affects serotonin, norepinephrine, cholinergic neurotransmission, neurosteroid synthesis, and oxytocin release.[11]
Pharmacokinetics
The sole controlled human pharmacokinetic study administered a single oral dose of 25 mg/kg to 8 healthy volunteers.[8] 1,4-BD reached peak plasma concentration at approximately 24 minutes and was eliminated with a half-life of about 39 minutes. The derived GHB metabolite peaked later (around 39 minutes after dosing) with a half-life of roughly 32 minutes.[8]
Compared to direct GHB administration, 1,4-BD produces a consistently longer duration of action owing to the rate-limiting ADH conversion step.[19][10] GHB crosses the blood-brain barrier via monocarboxylate transporters rather than passive diffusion,[23] and is eliminated through the tricarboxylic acid cycle without significant liver enzyme involvement.[14]
A critical pharmacokinetic variable is ADH1B genotype: carriers of the ADH1B G143A variant showed a four-fold reduction in 1,4-BD clearance,[8] predicting dramatic inter-individual variability in GHB production rate and peak effect intensity from the same dose.
Neuroscience[edit]
Where it acts
All neural effects of 1,4-butanediol are mediated through its GHB metabolite. At pharmacological concentrations, GHB activates GABA-B receptors on presynaptic terminals and postsynaptic neurons, hyperpolarizing cells through potassium channel opening and calcium channel inhibition.[18] This produces the sedative, muscle-relaxant, and anxiolytic core of the experience.
In the brain's reward circuit — the ventral tegmental area and nucleus accumbens — GHB disinhibits dopamine neurons through GABA-B signaling.[21][11] This mesolimbic dopamine surge underlies the euphoria and reinforcing quality at moderate doses; at higher doses, global GABAergic inhibition overwhelms the dopamine effect and sedation predominates.
Why it matters
Brain mapping reveals that GHB activates neural populations in the median raphe nuclei and lateral habenula — regions governing mood regulation and reward processing — that the pure GABA-B agonist baclofen does not reach.[24] These GHB-specific activations provide a neural basis for the prosocial, euphoric, and sexually arousing effects that distinguish GHB-type compounds from other GABA-B agents.
Chronic exposure triggers neuroadaptive changes across GABA-B, glutamate, GABA-A, dopamine, serotonin, and neurosteroid systems.[11] These plastic changes constitute the biological substrate of physical dependence — when the GHB stimulus is removed, compensatory glutamate overactivity drives the seizures, delirium, and autonomic instability characteristic of withdrawal.
The high-affinity GHB-specific binding site persists in GABA-B1 knockout mice,[17] but whether activating it is necessary for euphoria or therapeutic benefit remains unknown. Oxidative stress markers in animal studies[25] and cognitive deficits in chronic users[26] suggest possible neurotoxicity, but no human neuroimaging study has directly assessed structural brain changes from chronic use.
Subjective Effects[edit]
The 1,4-butanediol experience is shaped less by any unique pharmacology than by its prodrug conversion — the gradual enzymatic transformation to GHB produces a slower, gentler onset than direct GHB or GBL. At lower doses, warm sociability, euphoria, and disinhibition predominate; a modest increase tips the experience abruptly toward heavy sedation and amnesia. Set and setting modulate the balance between stimulatory and sedative dimensions, but dose is the dominant variable in a compound whose intensity curve is exceptionally steep.
Compared to alcohol — the most familiar GABAergic depressant — 1,4-BD produces more pronounced euphoria, greater enhancement of sexual arousal, and a sharper boundary between pleasurable effects and incapacitation. Compared to direct GHB, the onset is more gradual and the total duration longer, lending a smoother arc to the experience but extending the risk window.
Effect Grid
Clear euphoria, disinhibition, and enhanced sociability define this range. Music enhancement becomes apparent, sexual arousal enhancement is frequently reported, and cognitive euphoria produces a warm, contented mental state. Communication feels effortless and empathy enhancement may emerge. Laughter fits occur in social settings.
Motor control impairment becomes noticeable — coordination is visibly affected. Amnesia may begin, particularly at the upper boundary. Body high intensifies. Nausea occurs in some users. Thought deceleration and analysis suppression produce a cognitively relaxed state. Stimulation gives way to sedation as doses approach the upper end.
This range corresponds to the 25 mg/kg dose used in Thai 2007 (~1.7 mL). The steep dose-response curve means small increments above this range can produce disproportionate intensification. Volumetric dosing (mL) approximates mass dosing (g) due to near-unit density.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Music enhancement · Touch enhancement
Physical fatigue · Bodily heaviness · Dizziness · Tactile euphoria · Breathing alteration · Insomnia · Laughter fits · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Spontaneous body sensations · Body schema distortion · Headache · Heart rate perception changes · Pain suppression · Restlessness · Temperature dysregulation · Tingling / electric sensations · Brain zaps · Excessive sweating · Involuntary body movements · Trembling · Vomiting · Bodily dissociation
Tactile euphoria · Breathing alteration · Insomnia · Laughter fits · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Spontaneous body sensations · Body schema distortion · Headache · Heart rate perception changes · Pain suppression · Restlessness · Tingling / electric sensations · Brain zaps · Excessive sweating · Involuntary body movements · Trembling · Vomiting · Bodily dissociation
Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Memory suppression · Thought deceleration · Delusions of sobriety · Language suppression · Suggestibility enhancement · Thought disorganization · Aesthetic enhancement · Humor enhancement · Amnesia · Delirium
Information processing suppression · Memory fragmentation · Memory suppression · Thought deceleration · Language suppression · Suggestibility enhancement · Thought disorganization · Aesthetic enhancement · Humor enhancement · Amnesia · Delirium
Empathy enhancement · Anhedonia · Irritability · Anxiety · Dysphoria
Dysphoria
Communication suppression · Emotional susceptibility · Trust enhancement · Communication enhancement · Depersonalization · Derealization · Sociability suppression · Social disconnection · Cognitive disconnection
Depersonalization · Derealization · Sociability suppression · Social disconnection · Cognitive disconnection
Timeline
Minimal perceptible effects during the ADH conversion lag. Possible mild warmth or faint lightheadedness as 1,4-BD begins enzymatic conversion to GHB.
Gradual emergence of euphoria, relaxation, and sociability. Slower and smoother than GHB or GBL due to the rate-limiting ADH conversion step. Body warmth spreads.
Full expression of euphoria, disinhibition, and motor impairment. Amnesia risk increases. Plateau may be broader than GHB due to sustained enzymatic conversion maintaining GHB plasma levels.
Gradual transition from euphoria to sedation predominance. Drowsiness increases progressively. Motor impairment persists while cognitive effects begin to clear.
Residual drowsiness and mild cognitive fog. Some users report feeling refreshed upon waking if sleep occurred during the offset.
⚠ Do not drive or operate machinery for at least 6 hours after ingestion, or longer if any effects persist.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- baclofen
Toxicity
Acute toxicity
At overdose, 1,4-BD produces deep unconsciousness, slowed or stopped breathing, slowed heart rate, low body temperature, muscle jerks, and vomiting.[10] The blood concentration that produces euphoria and the concentration associated with fatal cardiorespiratory failure differ by roughly five-fold[7] — one of the narrowest margins among recreational depressants. Most episodes resolve within 2–6 hours with supportive care.[10][24]
1,4-BD–specific overdose features
Unlike direct GHB overdose, 1,4-BD poisoning produces an acid-base disturbance in the blood that mimics poisoning by methanol or antifreeze.[25] This can mislead emergency teams into applying the wrong treatment. Standard drug screens do not detect 1,4-BD; confirmation requires specialized laboratory analysis.[26][25]
Ethanol co-ingestion
Combining 1,4-butanediol with alcohol is uniquely dangerous. Alcohol blocks the enzyme that converts 1,4-BD to GHB,[15] causing unconverted 1,4-BD to accumulate in the body. When the alcohol clears, the accumulated 1,4-BD rapidly converts and produces a sudden, severe surge of intoxication.[3][25]
The pattern is deceptive: minimal effects during drinking, then sudden collapse hours later. This interaction has been implicated in fatal cases.
Fatalities
Deaths involving 1,4-BD and related GHB compounds have been documented in Australasia[12] and across all five Nordic countries.[13] Most involve multiple substances — particularly alcohol, opioids, or benzodiazepines.[12][13]
Chronic toxicity
Chronic use has been linked to deficits in working memory, attention, and executive function.[23] High-dose GHB produced oxidative stress in rat brain tissue.[27] No specific liver or kidney toxicity has been documented beyond the acid-base disturbance seen in acute overdose.[25]
Drug-facilitated sexual assault
GHB and 1,4-BD have been documented as agents of drug-facilitated sexual assault: they cause rapid incapacitation, produce amnesia, are nearly tasteless, and clear from the body within roughly 12 hours.[26][9]
Psychological Risks
- Amnesia: Memory blackouts are dose-dependent and can be total at moderate-to-high doses, creating vulnerability to exploitation and preventing accurate self-assessment of intoxication.[23]
- Disinhibition: Impaired judgment contributes to risky behavior and accidental injury.[6]
- Delusions of sobriety: Intoxicated people may believe they are less impaired than they are, compounded by amnesia.
- Psychological dependence: Severely dependent users develop compulsive redosing every 1–3 hours around the clock.[5]
- Post-withdrawal psychiatric effects: Persistent anxiety, insomnia, and depression are reported after stopping.[11]
Tolerance & Dependence
Tolerance develops within several weeks of continuous use. The adaptation occurs at GABA-B receptors — meaning standard benzodiazepine doses show limited effectiveness during withdrawal, because benzodiazepines act on a different receptor (GABA-A).[11]
GHB and 1,4-BD are highly physically and psychologically addictive.[5] Dependence involves adaptations across multiple brain systems including GABA, glutamate, dopamine, and serotonin.[11]
The tolerance reset duration in the database (10.5 days) has not been confirmed in published literature.citation needed
Withdrawal
GHB/1,4-BD withdrawal begins faster than alcohol or benzodiazepine withdrawal because GHB clears quickly from the body.[10][28] Features include:
- Anxiety, agitation, and irritability
- Insomnia
- Tremors
- Rapid heart rate and high blood pressure
- Auditory and visual hallucinations
- Profuse sweating
- Delirium — potentially rapid-onset
- Seizures
- Muscle breakdown[29]
Duration is typically 5–7 days; one case documented recurrent withdrawal over 56 days.[30]
Withdrawal can be life-threatening and requires medical management. Benzodiazepines are first-line but often show high resistance in severe cases.[5][31] Alternative treatments include baclofen,[32][33] phenobarbital for resistant cases,[34] pharmaceutical GHB (sodium oxybate) tapering,[5][6] and propofol in intensive care for the most severe presentations. Relapse rates are high.[5]
Drug Interactions
1,4-BD creates two distinct hazards: it amplifies the depressant effects of any other sedative, and — unique among GHB-type drugs — alcohol also blocks its conversion to GHB, creating a dangerous delayed surge when alcohol clears.
Ethanol
Alcohol both intensifies GHB's effects and delays the conversion of 1,4-BD to GHB.[3][15][25] Effects are blunted during drinking, then collapse arrives when the alcohol clears. Multiple fatalities have been attributed to this pattern.[10][12]
Opioids
Both suppress breathing and consciousness. Multiple deaths involve 1,4-BD or GHB combined with opioids.[12][13]
Benzodiazepines
Additive depression at intoxicating doses.[35][36] Benzodiazepines are used to treat GHB withdrawal — but combining them with active 1,4-BD intoxication is dangerous.
Other depressants
Barbiturates, sedative-hypnotics, antipsychotics, and ketamine all carry risk of additive depression when combined with 1,4-BD.[35]
NSAIDs (diclofenac)
Diclofenac may alter how much GHB reaches the brain by blocking a transporter. In animal studies it reduced brain GHB levels and lessened respiratory depression.[37] Clinical significance in humans is unknown.
Antiretroviral drugs
In chemsex settings, GHB-type compounds are often taken alongside antiretroviral medications.[38] Potential interactions with GHB transport or elimination have not been fully studied.
Contraindications
10 knownAbsolute
- Concurrent alcohol use: Risk of profound, unpredictable, and potentially fatal depression through dual mechanisms.[10][12]
- Concurrent opioid use: Additive respiratory depression; multiple documented fatalities.[12][13]
- Concurrent benzodiazepine or sedative use: Additive depression at intoxicating doses.[35][36]
- Active breathing difficulties: GHB causes dose-dependent respiratory depression; pre-existing impairment increases overdose risk.[10]
- Operating vehicles or machinery: sedation, motor impairment, and amnesia preclude safe operation.[10]
Relative
- Epilepsy or seizure history: GHB can affect seizure threshold, and withdrawal precipitates seizures.[10]
- ADH1B variant carriers: Slow conversion creates risk of delayed, extended, or paradoxically intense intoxication.[8]
- Pregnancy: No safety data exist.safety citation needed
- NSAID use (particularly diclofenac): Potential alteration of brain GHB levels; clinical significance unclear.[37]
Harm Reduction[edit]
Forms & Identification
1,4-Butanediol cannot be identified by appearance. It is a clear, slightly viscous liquid almost indistinguishable from water or GBL. No standard reagent test differentiates it from similar liquids. The only reliable confirmation of identity and purity is laboratory analysis such as GC-MS.
The most important concern is whether a sample labeled "BDO" or "1,4-BD" is actually what it claims. Mislabeled GBL would produce a faster and more intense onset at the same measured volume.
Guidelines
- Use a needleless syringe or graduated pipette to measure doses — never eyeball or pour from the bottle
- Start with the lowest effective dose and wait at least 90 minutes before considering redosing
- Never combine with alcohol, opioids, benzodiazepines, or any other depressant
- Always have a sober companion present who knows the substance, dose, and time taken
- Eat a light meal beforehand — an empty stomach accelerates onset and increases peak intensity
- Write down the time and amount of each dose to prevent amnesia-driven redosing
- Do not drive or operate machinery for at least 6 hours after the last dose
- Keep the substance in a clearly labeled container, stored separately from beverages
Set & Setting
The delayed onset — 30 to 60 minutes — tempts redosing before the first dose has peaked. This is a common pathway to overdose. A calm, familiar environment with trusted companions reduces harm during this unpredictable window.
The steep dose-response curve means sudden incapacitation is always possible. The space must be safe for that scenario: soft surfaces, no water hazards such as pools or baths, and at least one sober companion who knows what was taken and when.
Aftercare & integration. After a 1,4-BD session, prioritize sleep, hydration, and food. The GABAergic rebound effect after GHB clears can produce restlessness, anxiety, and insomnia — these are normal and typically resolve within 12–24 hours.
If use has been more than occasional, watch for early signs of dependence: difficulty sleeping without dosing, shortening intervals between doses, or agitation within hours of the last dose. These signal physical adaptation and warrant reassessment before a compulsive pattern takes hold.
Recovery & Support
GHB/1,4-BD dependence is one of the most physically dangerous dependencies to manage without medical help. Do not stop abruptly after a period of around-the-clock dosing — withdrawal seizures and delirium can begin within hours and may be life-threatening.
Medical detoxification is strongly recommended. Options include supervised benzodiazepine protocols, baclofen tapering, and in some European countries, pharmaceutical GHB (sodium oxybate) tapering programs. Relapse rates are high; ongoing support through addiction medicine, peer groups, and mental health treatment improves outcomes.
For immediate help:
- SAMHSA National Helpline (US): 1-800-662-4357
- FRANK (UK): 0300 123 6600
- Counselling Online (Australia): 1800 888 236
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Unresponsive to voice or firm stimulation (sternal rub)
- Slow, irregular, or stopped breathing
- Vomiting while unconscious
- Blue or grey discoloration of lips or fingertips
- Seizure activity
Immediate steps:
- 1. Call emergency services immediately — do not wait to see if they "sleep it off"
- 2. Place the person on their side (recovery position) to prevent choking on vomit
- 3. Monitor breathing continuously until help arrives
- 4. Do NOT induce vomiting
- 5. Do NOT leave the person alone
What to tell the dispatcher: Provide the substance name (1,4-butanediol or BDO — tell them it converts to GHB in the body), the approximate amount taken, the time of ingestion, and current symptoms. Note any other substances taken, especially alcohol. Good Samaritan laws in many jurisdictions protect callers from prosecution when seeking medical help for a drug emergency.
No reversal agent exists for GHB or 1,4-BD overdose. Treatment is supportive: airway management and monitoring until the drug clears.
Legal Status[edit]
1,4-Butanediol occupies an unusual legal position. Its primary identity as a bulk industrial chemical — used to manufacture plastics and solvents — has complicated scheduling efforts across jurisdictions, even as its metabolite GHB is widely controlled.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not individually scheduled under the CSA | Subject to Federal Analogue Act prosecution when intended for human consumption; courts have upheld 1,4-BD as "substantially similar" to GHB. GHB itself is Schedule I (Schedule III as Xyrem). GBL is a DEA List I chemical.[39][4] |
| United Kingdom | Class C (Misuse of Drugs Act, since 2009) | Exception for industrial import/export/supply unless the supplier knows or believes the substance will be used for human ingestion.[39] |
| Australia | Border-controlled drug (since March 2024) | Illegal importation carries penalties up to life imprisonment.[39] |
| France | Banned (since September 2, 2011) | Sale and supply of raw 1,4-BD or products exceeding 10% concentration and 100 mL volume prohibited. Over 200 poisoning cases and 1 death reported since 2005.[40] |
| Germany | Not explicitly controlled under current NpSG | Cabinet-adopted amendment planned to add GBL and 1,4-BD to controlled substance schedules.citation needed |
| European Union | No EU-wide scheduling | ANSES (France) proposed EU-wide REACH restriction in 2012; not implemented at EU level as of 2024.[40] |
| Canada | Status unclear | GHB is Schedule III under CDSA; 1,4-BD's explicit scheduling status has not been confirmed.citation needed |
Analog and prodrug considerations
In the United States, the Federal Analogue Act allows prosecution when a substance closely resembles a Schedule I drug in structure and effect and is intended for human use. Courts have upheld this application to 1,4-BD.[39] Possession for legitimate industrial purposes remains legal — enforcement turns on proving intent.
Legal status varies by jurisdiction and changes frequently. This information is not legal advice.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- baclofen
Toxicity
Acute toxicity
No human lethal dose has been established for 1,4-butanediol. The primary danger is dose-dependent suppression of consciousness and breathing caused by the GHB metabolite. Plasma GHB concentrations of approximately 100 mg/L produce euphoria, while concentrations approaching 500 mg/L have been associated with fatal cardiorespiratory failure[7] — a five-fold range defining a dangerously narrow margin between desired effects and death.
Standard overdose presents with deep unconsciousness, slowed or stopped breathing, slowed heart rate, low body temperature, involuntary muscle jerks, and vomiting.[10] Vomiting while unconscious poses a serious choking risk. Most episodes resolve within 2–6 hours with supportive care.[10][27]
1,4-BD–specific overdose features
Unlike direct GHB overdose, 1,4-butanediol poisoning produces high anion gap metabolic acidosis and elevated osmol gap from the parent compound and its intermediary metabolites.[28] These laboratory findings mimic toxic alcohol poisoning (methanol, ethylene glycol), creating diagnostic confusion in emergency departments and potentially leading to inappropriate treatment.
1,4-BD is not detected by standard drug screens; identification requires specialized laboratory testing (GC-MS),[29] though the metabolic pattern can raise clinical suspicion before laboratory confirmation.[28]
Ethanol co-ingestion
Combining 1,4-butanediol with alcohol is uniquely dangerous through a dual mechanism. Alcohol competitively blocks the enzyme (ADH) that converts 1,4-BD to GHB,[15] causing unconverted 1,4-BD to accumulate in the body. When alcohol is metabolized and clears, the accumulated 1,4-BD rapidly converts to GHB, producing a delayed but potentially massive surge.[3][28]
The result is a deceptive pattern: minimal initial effects during drinking, followed by sudden severe unconsciousness hours later. This interaction has been implicated in fatal cases.
Fatalities
Deaths involving GHB and its precursors including 1,4-BD have been documented across multiple countries. An Australasian case series identified fatalities specifically linked to GHB-type compounds,[12] and GHB was found in fatal poisoning cases across all five Nordic countries.[13] The majority of deaths involve multiple substances, particularly combinations with alcohol, opioids, or benzodiazepines.[12][13]
Chronic toxicity
High-dose GHB derived from 1,4-BD induced oxidative stress in rat brain tissue.[25] Chronic use in humans has been associated with cognitive impairment including deficits in working memory, attention, and executive function.[26] No specific liver or kidney toxicity has been documented beyond the metabolic acidosis seen in acute overdose.[28]
Drug-facilitated sexual assault
GHB and its prodrug 1,4-BD have been documented as agents of drug-facilitated sexual assault owing to rapid incapacitation, production of amnesia, near-tastelessness, and rapid elimination from the body (detection window under 12 hours).[29][9]
Psychological Risks
- Amnesia: Memory blackouts are dose-dependent and can be total at moderate-to-high doses, creating vulnerability to exploitation and preventing accurate self-assessment of intoxication.[26]
- Disinhibition: Impaired judgment contributes to risky sexual behavior and accidental injury.[6]
- Delusions of sobriety: Users may believe they are less impaired than they are, a perception compounded by amnesia.
- Psychological dependence: Severely dependent users develop compulsive redosing patterns, dosing every 1–3 hours around the clock.[5]
- Post-withdrawal psychiatric effects: Persistent anxiety, insomnia, and depression are reported following cessation.[11]
Tolerance & Dependence
Tolerance develops within several weeks of continuous use and is GABA-B receptor–mediated: chronic GHB exposure produces cross-tolerance to baclofen but not to benzodiazepines.[11] This has a critical clinical consequence — standard benzodiazepine doses show limited effectiveness during withdrawal because the primary adaptation occurs at GABA-B, not GABA-A, receptors.
The tolerance reset duration in the database (10.5 days) has not been confirmed in published literature.citation needed
GHB and its precursors including 1,4-BD are highly physically and psychologically addictive.[5] Dependence involves chronic adaptations across GABA-B, GABA-A, glutamate, dopamine, serotonin, norepinephrine, cholinergic, and neurosteroid systems.[11]
Withdrawal
GHB/1,4-BD withdrawal progresses faster than alcohol or benzodiazepine withdrawal owing to GHB's short half-life.[10][30] Features include:
- Anxiety, agitation, and irritability
- Insomnia
- Tremors
- Rapid heart rate and high blood pressure
- Auditory and visual hallucinations
- Profuse sweating
- Delirium — potentially rapid-onset
- Seizures
- Muscle breakdown[31]
Duration is typically 5–7 days; one case documented recurrent withdrawal over 56 days.[32]
Withdrawal can be life-threatening and requires medical management. Benzodiazepines are first-line treatment but show high resistance in severe cases.[5][33] Alternative agents include baclofen,[34][35] phenobarbital for resistant cases,[36] pharmaceutical GHB (sodium oxybate) tapering,[5][6] and propofol in intensive care for the most severe presentations. Relapse rates are high.[5]
Drug Interactions
1,4-BD creates two distinct interaction mechanisms: synergistic depression of the central nervous system (shared with all depressants) and ADH competition (unique to 1,4-BD as a prodrug requiring enzymatic activation).
Ethanol
The most dangerous and counterintuitive interaction. Alcohol both intensifies GHB's depressant effects and competitively blocks its formation from 1,4-BD.[3][15][28] This produces delayed-onset severe intoxication: blunted effects during drinking, then sudden collapse when alcohol clears. Multiple fatalities have been attributed to this interaction.[10][12]
Opioids
Additive suppression of breathing and consciousness. Multiple fatalities involve GHB/1,4-BD combined with opioids.[12][13]
Benzodiazepines
Additive depression at intoxicating doses.[37][38] Paradoxically, benzodiazepines are used therapeutically to manage GHB withdrawal — but combining them with active 1,4-BD intoxication is dangerous.
Other depressants
Barbiturates, sedative-hypnotics, antipsychotics, and ketamine all carry risk of additive depression when combined with 1,4-BD.[37]
NSAIDs (diclofenac)
Diclofenac may alter GHB distribution in the brain by inhibiting monocarboxylate transporters. In animal studies, it reduced brain GHB levels and lessened respiratory depression.[39] Clinical significance in humans is unknown.
Antiretroviral drugs
In chemsex contexts, GHB-type compounds are frequently combined with antiretroviral medications containing enzyme inhibitors (ritonavir, cobicistat).[40] Although 1,4-BD metabolism does not involve the affected enzymes, potential interactions with GHB transport or elimination have not been fully studied.
Contraindications
10 knownAbsolute
- Concurrent alcohol use: Risk of profound, unpredictable, and potentially fatal depression through the dual ADH competition and synergistic mechanism.[10][12]
- Concurrent opioid use: Additive respiratory depression; multiple documented fatalities.[12][13]
- Concurrent benzodiazepine or sedative use: Additive depression at intoxicating doses.[37][38]
- Active breathing difficulties: GHB produces dose-dependent respiratory depression; pre-existing impairment increases overdose risk.[10]
- Operating vehicles or machinery: Motor impairment, sedation, and amnesia preclude safe operation.[10]
Relative
- Epilepsy or seizure history: GHB can modulate seizure threshold, and withdrawal precipitates seizures.[10]
- ADH1B variant carriers: Unpredictably slow conversion creates risk of delayed, extended, or paradoxically intense intoxication.[8]
- Pregnancy: No safety data exist.safety citation needed
- NSAID use (particularly diclofenac): Potential alteration of GHB brain distribution; clinical significance unclear.[39]
Harm Reduction[edit]
Forms & Identification
1,4-Butanediol cannot be identified by appearance alone — it is a clear, slightly viscous liquid virtually indistinguishable from water, GBL, or several other industrial solvents. No standard reagent test kit differentiates 1,4-BD from GBL or other clear liquids. The only reliable method to confirm identity and purity is laboratory-grade analysis such as GC-MS.
The most important identification concern is whether a sample labeled "BDO" or "1,4-BD" is actually the correct substance at the correct concentration. Mislabeled GBL sold as 1,4-BD would produce faster onset and require different dosing due to GBL's distinct conversion pathway and potency profile.
Guidelines
- Use a needleless syringe or graduated pipette to measure doses — never eyeball or pour from the bottle
- Start with the lowest effective dose and wait at least 90 minutes before considering redosing
- Never combine with alcohol, opioids, benzodiazepines, or any other depressant
- Always have a sober companion present who knows the substance, dose, and time taken
- Eat a light meal beforehand — an empty stomach accelerates onset and increases peak intensity
- Write down the time and amount of each dose to prevent amnesia-driven redosing
- Do not drive or operate machinery for at least 6 hours after the last dose
- Keep the substance in a clearly labeled container, stored separately from beverages
Set & Setting
1,4-BD's prodrug pharmacokinetics create specific set-and-setting considerations. The delayed onset (30–60 minutes) tempts redosing before the first dose has taken full effect — a common pathway to overdose. A calm, familiar environment with trusted companions reduces harm during the unpredictable onset window.
The steep dose-response curve means the environment must be safe for sudden incapacitation: soft surfaces, no water hazards (pools, baths), and at least one sober companion who knows what was taken and when.
Aftercare & integration. After a 1,4-BD session, prioritize sleep, hydration, and nutritional recovery. The GABAergic rebound effect following GHB clearance can produce restlessness, anxiety, and insomnia — these are normal and typically resolve within 12–24 hours.
If use has been more than occasional, monitor for early signs of dependence: difficulty sleeping without dosing, shortening intervals between doses, or feeling agitated within hours of the last dose. These signal the beginning of physical adaptation and should prompt reassessment before a compulsive pattern establishes itself.
Recovery & Support
GHB/1,4-BD dependence is one of the most physically dangerous substance dependencies to manage without medical help. Do not attempt to stop abruptly after a period of around-the-clock dosing — withdrawal seizures and delirium can begin within hours and may be life-threatening.
Medical detoxification is strongly recommended. Treatment options include supervised benzodiazepine protocols, baclofen tapering, and in some European countries, pharmaceutical GHB (sodium oxybate) tapering programs. Relapse rates are high; ongoing support through addiction medicine services, peer support groups, and mental health treatment improves outcomes.
For immediate help:
- SAMHSA National Helpline (US): 1-800-662-4357
- FRANK (UK): 0300 123 6600
- Counselling Online (Australia): 1800 888 236
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Unresponsive to voice or firm stimulation (sternal rub)
- Slow, irregular, or stopped breathing
- Vomiting while unconscious
- Blue or grey discoloration of lips or fingertips
- Seizure activity
Immediate steps:
- 1. Call emergency services immediately — do not wait to see if they "sleep it off"
- 2. Place the person on their side (recovery position) to prevent choking on vomit
- 3. Monitor breathing continuously until help arrives
- 4. Do NOT induce vomiting
- 5. Do NOT leave the person alone
What to tell the dispatcher: Provide the substance name (1,4-butanediol or BDO — tell them it converts to GHB in the body), the approximate amount taken, the time of ingestion, and current symptoms. Note any other substances taken, especially alcohol. Good Samaritan laws in many jurisdictions protect callers from prosecution when seeking medical help for a drug emergency.
No reversal agent exists for GHB or 1,4-BD overdose. Treatment is supportive: airway management and monitoring until the drug clears.
Legal Status[edit]
1,4-Butanediol occupies an unusual regulatory position. Unlike its metabolite GHB (widely scheduled as a controlled substance) and its structural relative GBL (often classified as a listed precursor), 1,4-BD's primary identity as a bulk industrial commodity has complicated scheduling efforts across jurisdictions. Its legitimate commercial applications — in tetrahydrofuran production, polyurethane manufacture, and as an industrial solvent — create tension between drug control objectives and chemical industry requirements.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not individually scheduled under the CSA | Subject to Federal Analogue Act prosecution when intended for human consumption; courts have upheld 1,4-BD as "substantially similar" to GHB. GHB itself is Schedule I (Schedule III as Xyrem). GBL is a DEA List I chemical.[41][4] |
| United Kingdom | Class C (Misuse of Drugs Act, since 2009) | Exception for industrial import/export/supply unless the supplier knows or believes the substance will be used for human ingestion.[41] |
| Australia | Border-controlled drug (since March 2024) | Illegal importation carries penalties up to life imprisonment.[41] |
| France | Banned (since September 2, 2011) | Sale and supply of raw 1,4-BD or products exceeding 10% concentration and 100 mL volume prohibited. Over 200 poisoning cases and 1 death reported since 2005.[42] |
| Germany | Not explicitly controlled under current NpSG | Cabinet-adopted amendment planned to add GBL and 1,4-BD to controlled substance schedules.citation needed |
| European Union | No EU-wide scheduling | ANSES (France) proposed EU-wide REACH restriction in 2012; not implemented at EU level as of 2024.[42] |
| Canada | Status unclear | GHB is Schedule III under CDSA; 1,4-BD's explicit scheduling status has not been confirmed.citation needed |
Analog and prodrug considerations
1,4-Butanediol's regulatory treatment is shaped by its prodrug status. In the United States, the Federal Analogue Act permits prosecution when a substance is "substantially similar" to a Schedule I or II controlled substance in structure and pharmacological effect, provided it is intended for human consumption. Federal courts have upheld this application to 1,4-BD.[41]
The compound's widespread industrial use means that possession or sale for legitimate chemical purposes remains legal, creating an enforcement challenge centered on proving intent.
Frequently asked questions
What is 1,4-Butanediol?
1,4-Butanediol is a synthetic diol and prodrug of GHB, converted via alcohol dehydrogenase to produce depressant effects at GABA-B receptors. It emerged as a GHB substitute after GHB scheduling in 2000, with delayed onset and extended duration relative to GHB.
How long does 1,4-Butanediol last?
Total duration by route of administration — Oral: 3 – 5 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 1,4-Butanediol?
Psychedex publishes a dosage table for 1,4-Butanediol on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 1,4-Butanediol?
The highest-severity documented interactions for 1,4-Butanediol: GHB, GBL (Lethal), Ketamine, DXM, PCP (Lethal), Opioids (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 1,4-Butanediol addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 1,4-Butanediol: tolerance builds moderate; full reset takes 10.5 days; cross-tolerance develops with baclofen. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abMathivet P, Bernasconi R, De Barry J, et al. (1997) Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABAB receptor agonist — European Journal of Pharmacology PMID:9083788
- [2] ^abLingenhoehl K, Brom R, Heid J, et al. (1999) Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors — Neuropharmacology PMID:10587082
- [3] ^abcdPoldrugo F, Snead OC (1984) 1,4 Butanediol, gamma-hydroxybutyric acid and ethanol: relationships and interactions — Neuropharmacology PMID:6717752
- [4]
- [5]
- [6]
references
- [1] ^abMathivet P, Bernasconi R, De Barry J, et al. (1997) Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABAB receptor agonist — European Journal of Pharmacology PMID:9083788
- [2] ^abLingenhoehl K, Brom R, Heid J, et al. (1999) Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors — Neuropharmacology PMID:10587082
- [3] ^abcdPoldrugo F, Snead OC (1984) 1,4 Butanediol, gamma-hydroxybutyric acid and ethanol: relationships and interactions — Neuropharmacology PMID:6717752
- [4]
- [5]
- [6]